Invivyd’s (IVVD) “Buy” Rating Reaffirmed at HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock.

Invivyd Stock Performance

IVVD opened at $0.91 on Tuesday. The firm’s 50-day simple moving average is $0.99 and its 200-day simple moving average is $1.41. Invivyd has a twelve month low of $0.81 and a twelve month high of $5.20. The firm has a market cap of $108.59 million, a price-to-earnings ratio of -0.49 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $4.91 million. As a group, sell-side analysts anticipate that Invivyd will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Invivyd

A number of hedge funds have recently added to or reduced their stakes in IVVD. SG Americas Securities LLC acquired a new position in Invivyd during the 1st quarter valued at about $56,000. XTX Topco Ltd lifted its position in Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares during the period. Tidal Investments LLC acquired a new position in Invivyd during the 1st quarter valued at about $126,000. Marshall Wace LLP lifted its position in Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in shares of Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the period. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.